Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited has requested a trading halt on its securities pending a significant announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move indicates a strategic shift that could potentially impact the company’s market positioning and stakeholder interests.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company that specializes in the development and manufacturing of branded and generic pharmaceuticals. The company focuses on providing high-quality, affordable medications to improve patient health outcomes.
Average Trading Volume: 458,975
Technical Sentiment Signal: Sell
Current Market Cap: A$389.2M
See more data about MYX stock on TipRanks’ Stock Analysis page.